Publication details
Novinky v léčbě chronického srdečního selhání – guidelines ČKS 2011 – srovnání s minulými doporučeními
| Title in English | Novelties in the treatment of chronic heart failure – the 2011 guidelines of the Czech Society of Cardiology – comparison with the previous guidelines |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | heart failure; recommendation; drug therapy |
| Description | The new guidelines of the Czech Society of Cardiology for the diagnosis and treatment of chronic heart failure (CHF) were first presented and reviewed in autumn 2011. Angiotensin converting enzyme (ACE) inhibitors and beta blockers (BB) remain the first-line therapies for CHF. The following changes have been made to the drug therapy of CHF in the new guidelines: higher dose therapy with ACE inhibitors and sartanes (angiotensin receptor blockers – ARBs) is recommended in line with clinical studies, the need is stressed for instructing the patient receiving BB to be aware of possible worsening of his/her condition, a heart rate of < 70/m beats per minute is recommended, the indication of aldosterone receptor blockers (ARB) is extended to include NYHA II patients, a new class of drugs – If channel blockers – is introduced, the anticoagulant therapy in heart failure is defined, and a new perspective is presented on the use of hypolipidemic drugs in patients with heart failure and coronary heart disease (CHD). |